Orexin 2 Receptor (OX2R) Protein Distribution Measured by Autoradiography Using Radiolabeled OX2R-Selective Antagonist EMPA in Rodent Brain and Peripheral Tissues

doi:10.21203/rs.3.rs-1144161/v1

Download PDF

Research Article

Orexin 2 Receptor (OX2R) Protein Distribution Measured by Autoradiography Using Radiolabeled OX2R-Selective Antagonist EMPA in Rodent Brain and Peripheral Tissues

https://doi.org/10.21203/rs.3.rs-1144161/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 18 May, 2022

Read the published version in Scientific Reports →

You are reading this latest preprint version

Orexin, a neuropeptide, performs various physiological functions, including the regulation of emotion, feeding, metabolism, respiration, and sleep/wakefulness, by activating the orexin 1 receptor and orexin 2 receptor (OX2R). Owing to the pivotal role of OX2R in wakefulness and other biological functions, OX2R agonists are being developed. A detailed understanding of OX2R protein distribution is essential for determining the mechanisms of action of OX2R agonists; however, this has been hindered by the lack of selective antibodies. In this study, we first confirmed the OX2R-selective binding of [³H]-EMPA in in vitro autoradiography studies, using brain slices from OX2R knockout mice and their wild-type littermates. Subsequently, OX2R protein distribution in rats was comprehensively assessed in 51 brain regions and 10 peripheral tissues using in vitro autoradiography with [³H]-EMPA. The widespread distribution of OX2R protein, including that in previously unrecognized regions of the retrosplenial cortex and suprachiasmatic nucleus of the hypothalamus, was identified. In contrast, negligible/very low OX2R protein expression was observed in peripheral tissues, suggesting that orexin exerts OX2R-dependent physiological functions primarily through activation of the central nervous system. These data would be useful for understanding the wide range of biological functions of OX2R and the application of OX2R agonists in various disorders.

Drug Discovery, Design, & Development

Orexin

autoradiography studies

biological functions

OX2R agonists

Orexin, also known as hypocretin, was initially discovered as a regulator of feeding behavior in the hypothalamus [1,2]. Two endogenous orexin peptides, orexin-A and orexin-B, are cleaved from the single precursor prepro-orexin peptide [1,2]. Despite its restricted localization in the lateral hypothalamus, orexin neurons form widespread projections throughout the brain [3,4]. At the terminal, they activate two G protein-coupled receptors: orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R) [1]. OX1R has a greater binding affinity for orexin-A than orexin-B, whereas OX2R has a similar affinity for both peptides [1]. The loss of orexin neurons causes narcolepsy type 1 (NT1), characterized by excessive daytime sleepiness and cataplexy [5-9]. OX2R knockout (KO) mice, but not OX1R KO mice, show NT1-like phenotypes, including clear fragmentation of wakefulness and cataplexy-like episodes [10,11]. In addition, a null mutation in the OX2R gene was observed to produce a distinct narcolepsy-like phenotype in dogs [12]. Therefore, OX2R appears to play a pivotal role in the pathophysiology of NT1. Apart from regulating wakefulness and cataplexy, orexin is also implicated in multiple biological functions, including emotion, emotional memory, motivation, reward system, feeding, energy homeostasis/metabolism, stress responses, and autonomic function [10,13,14].

We have recently discovered highly selective OX2R agonists [15] that are currently under clinical investigation as novel treatment agents for NT1 and other disorders associated with hypersomnia. Considering the broad spectrum of biological functions of orexin, the profiling of OX2R expression in conjunction with its functional analysis could help maximize the therapeutic value of OX2R agonists. Comprehensive OX2R mRNA expression analysis has revealed the widespread distribution of OX2R in the central nervous system, with particularly high expression in the hippocampus as well as in various nuclei in the hypothalamus, and undetectable expression in the cerebellum [16,17]. In addition, the peripheral expression of OX2R mRNA has been reported in previous studies [1,18]. The expression profiling of OX2R protein has proven to be more beneficial than that of OX2R mRNA for the understanding of the pharmacological functions of OX2R agonists. However, research on this topic has been hindered thus far because of the lack of OX2R-selective antibodies.

In vitro autoradiography is a useful method for evaluating the distribution and abundance of receptor proteins when a highly selective radioligand is available [19]. N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA) was previously reported as a high-affinity, reversible, and OX2R-selective antagonist [20]. Nonetheless, its specificity to OX2R has not been fully investigated in in vitro autoradiography studies.

In this study, the selectivity of [³H]-EMPA for OX2R protein was assessed in in vitro autoradiography experiments using brain sections obtained from OX2R KO mice and their wild-type (WT) littermates. Under similar conditions using [³H]-EMPA as an OX2R-selective radioligand, OX2R protein distribution was comprehensively evaluated in 51 brain regions and 10 peripheral tissues of rats. Subsequently, OX2R protein and mRNA distributions were compared using previously reported mRNA expression data. Our data showed the extensive distribution of OX2R protein expression, including previously unrecognized OX2R expression, in the rat brain, whereas in contrast, the peripheral tissues contained nearly undetectable or very low levels of the protein. Although the elucidation of OX2R functions in each region will require further investigation, our results may provide essential information on the therapeutic effects and side effects of OX2R-selective agonists.

Selectivity of [ ³ H]-EMPA for OX2R in in vitro autoradiography

The selectivity of the radioligand is critical for evaluating the distribution and abundance of target proteins using in vitro autoradiography [19]. First, the selectivity of [³H]-EMPA for OX2R was evaluated by comparing the distribution of [³H]-EMPA in brain sections obtained from OX2R KO mice and their WT littermates. Considering the diurnal fluctuation in orexin levels [21-23], a corresponding variation in OX2R protein expression was anticipated. Therefore, all animals were sacrificed, and their brains were collected at approximately the same time (13:00–15:00). As depicted in the representative autoradiographs with brain sections from WT mice (Fig. 1a), a high density of [³H]-EMPA binding was observed in specific brain regions, including the hippocampus, nucleus accumbens, and pontine nuclei. These bindings apparently disappeared in brain sections from OX2R KO mice (Fig. 1b). The extent of specific binding of [³H]-EMPA to OX2R was evaluated in terms of the relative optical density (ROD) in six brain regions (nucleus accumbens, internal layer of cortex, hippocampus, hypothalamus, superior colliculus, and pontine nuclei) by calculating the difference in [³H]-EMPA binding between the brain sections isolated from WT mice and OX2R KO mice; the latter was considered to represent non-specific binding (NSB) (Fig. 1c). A relatively high density of [³H]-EMPA binding was observed in the nucleus accumbens, hippocampus, and pontine nuclei. Brain sections isolated from OX2R KO mice are not always useful for assessing NSB under various conditions for estimating the specific binding of [³H]-EMPA to OX2R. Therefore, NSB was also assessed in the presence of 10 µM JNJ-10397049, a selective and potent OX2R antagonist with more than 500-fold selectivity over OX1R [24,25]. As shown in the representative autoradiographs with brain sections from WT mice (Fig. 1d), [³H]-EMPA binding, as observed in Fig. 1a, disappeared in the presence of 10 µM JNJ-10397049. The specific binding of [³H]-EMPA to OX2R in the brain sections from WT mice was obtained by subtracting NSB with 10 µM JNJ-10397049 from total binding (Fig. 1c). The ROD values determined based on NSB in the presence of 10 µM JNJ-10397049 or in brain sections from OX2R KO mice were considerably similar in all six regions of the brain that were analyzed (Fig. 1c). Therefore, the binding of [³H]-EMPA in the brain sections from WT mice was highly selective for OX2R when NSB was assessed using JNJ-10397049.

Distribution and abundance of OX2R protein in rat brain sections

To further investigate OX2R protein expression, the distribution and density of [³H]-EMPA binding were evaluated in rat brain sections, but not in mouse brain sections, to improve the accuracy in the analysis of [³H]-EMPA binding in small brain regions. All brains were collected at approximately the same time (8:00–9:00) to avoid potential circadian variations. As depicted in Fig. 2a and 2b, a relatively high density of [³H]-EMPA binding was observed in certain regions of the brain, including the nucleus accumbens and hippocampus. These bindings almost completely disappeared in the presence of excess JNJ-10397049 (final concentration of 1 µM) [24,25], as depicted in Fig. 2c and 2d. The density of specific binding of [³H]-EMPA to OX2R was evaluated in six regions (nucleus accumbens, internal layer of cortex, hippocampal dentate gyrus, mammillary nuclei of hypothalamus, superior colliculus, and pontine nuclei) of the rat brain sections (Fig. 2e). A relatively high density of [³H]-EMPA binding was observed in the nucleus accumbens, hippocampus, and pontine nuclei of the rat brain sections, as seen in the mouse brain sections (Fig. 1c and 2e). Therefore, the experimental conditions were suitable for evaluating OX2R protein distribution and abundance in the rat brain sections using [³H]-EMPA.

Under such conditions, the distribution and density of [³H]-EMPA binding were evaluated in 51 regions of the rat brain sections. As expected from the widespread distribution of OX2R mRNA expression, an extensive distribution of [³H]-EMPA binding was observed in the rat brain sections (Fig. 3, Table 1, and Supplementary Table S1). A very high density of [³H]-EMPA binding (ROD ≥ 12) was observed in the hippocampal dentate gyrus, nucleus accumbens (shell), and cortical amygdala. A high density of [³H]-EMPA binding (8 ≤ ROD < 12) was also observed in the retrosplenial cortex, ventral pallidum, hypothalamus (suprachiasmatic nucleus, paraventricular nucleus, and ventral tuberomammillary nucleus), central medial thalamic nucleus, and pontine nuclei. A moderate density of [³H]-EMPA binding (4 ≤ ROD < 8) was observed in the piriform cortex, infralimbic cortex, prelimbic cortex, cingulate cortex, internal layer of cortex, hippocampal CA1 and CA3, septum (lateral, medial, and laterodorsal parts), globus pallidus, basolateral amygdala, preoptic area of hypothalamus (magnocellular, lateral and medial area), mammillary nuclei of hypothalamus, thalamus (medial geniculate nucleus, ventromedial nucleus, and laterodorsal nucleus), periaqueductal gray, dorsal raphe nucleus, median raphe nucleus, locus coeruleus, pedunculopontine tegmental nucleus, laterodorsal tegmental nucleus, Barrington’s nucleus, and pre-Bötzinger complex. A low density of [³H]-EMPA binding (1 ≤ ROD < 4) was observed in the motor cortex, somatosensory cortex, insular cortex, cerebellum, triangular septum, caudate putamen, nucleus accumbens (core), subfornical organ, dorsomedial and ventromedial nucleus of the hypothalamus, dorsolateral geniculate nucleus of the thalamus, superior colliculus, and ventral tegmental area. Additionally, negligible [³H]-EMPA binding density (ROD < 1) was observed in the substantia nigra. Table 1 also includes the comparison between the qualitative estimates of OX2R protein levels in this study and previously reported OX2R mRNA levels [16,17]. Eight brain regions (cingulate cortex, insular cortex, cerebellum, hippocampal CA1 and dentate gyrus, nucleus accumbens shell, cortical amygdala, and ventromedial thalamic nucleus) showed a relatively higher OX2R protein expression than the reported mRNA expression, whereas there were no brain regions with relatively lower OX2R protein expression than the reported mRNA expression [16,17].

Distribution and abundance of OX2R protein in rat peripheral tissue sections

The peripheral expression of OX2R mRNA, along with OX2R functions, has been reported previously [1,18]. In the present study, we evaluated the distribution and density of [³H]-EMPA binding in 10 peripheral tissue sections of rats (Fig. 4, Table 2, and Supplementary Table S2). All tissues or organs were collected at approximately the same time (8:00–9:00) to avoid potential circadian variations. NSB was evaluated in the presence of 1 µM JNJ-10397049. A very low density of [³H]-EMPA binding (1 ≤ ROD < 2.5) was observed in the adrenal and kidney cortices. A negligible density of [³H]-EMPA binding (ROD < 1) was observed in the heart, testis, adrenal medulla, gut (mucosa and muscle), pituitary gland, skeletal muscle, thyroid, lung, and bladder muscle. Table 2 also presents the comparison between the qualitative estimates of OX2R protein levels in this study and the previously reported OX2R mRNA levels [1,18]. Compared to the reported OX2R mRNA levels, relatively higher OX2R protein expression was observed in the kidney cortex, whereas relatively lower OX2R protein expression was observed in the adrenal and pituitary glands.

This study presented a comprehensive assessment of OX2R protein distribution and abundance in rat brain sections and peripheral tissue sections using in vitro autoradiography, with [³H]-EMPA as an OX2R-selective radioligand. [³H]-EMPA binding was abolished in brain slices from OX2R KO mice, suggesting the high selectivity of [³H]-EMPA to OX2R. The specific binding density of [³H]-EMPA to OX2R in brain sections from WT mice determined using NSB under excess JNJ-10397049 or in brain sections from OX2R KO mice were quite similar. Therefore, the evaluation of NSB using JNJ-10397049 is useful for estimating OX2R protein levels based on [³H]-EMPA binding. Using OX2R-specific autoradiography with [³H]-EMPA in rat brain and peripheral tissue sections, we observed widespread OX2R protein distribution in the brain, with high expression in several specific regions, whereas peripheral OX2R protein expression was negligible or very low.

Consistent with findings from a previously reported autoradiography study [20], in which [³H]-EMPA was used in combination with the OX2R-selective antagonist Cp-5 (exhibiting more than 250-fold selectivity for OX2R over OX1R [26]) for estimating NSB, a high density of [³H]-EMPA binding was observed in the nucleus accumbens, hippocampus, internal layer of cortex, tuberomammillary nucleus of the hypothalamus, several thalamic nuclei, and pontine nuclei of the rat brain sections. A high density of binding in the nucleus accumbens shell, yet low density of binding in the core, was also found to be congruous. Therefore, autoradiography using [³H]-EMPA can be an effective method to accurately and reproducibly measure the OX2R protein distribution.

To our knowledge, two studies have conducted a comprehensive assessment of OX2R mRNA expression in the rat brain [16,17], and two studies have reported the expression in peripheral tissues in rats [1,18]. Compared to the previously reported OX2R mRNA expression levels, we observed higher OX2R protein levels in eight brain regions (cingulate cortex, insular cortex, cerebellum, hippocampal CA1 and dentate gyrus, nucleus accumbens shell, cortical amygdala, and ventromedial thalamic nucleus) and in the kidney cortex, whereas lower levels were observed in two peripheral tissues (adrenal and pituitary glands). The reasons underlying this difference in mRNA and protein levels are unknown. However, besides post-transcriptional regulation, OX2R protein expression at the presynaptic terminals of projecting neurons could contribute to the difference in expression in the target regions of the brain. Nevertheless, the protein distribution profile is more pertinent than the mRNA expression profile for understanding OX2R function. We also observed that OX2R protein expression was relatively high in the retrosplenial cortex, ventral pallidum, and suprachiasmatic nucleus of the hypothalamus and moderate in the prelimbic cortex, basolateral amygdala, medial geniculate, and laterodorsal thalamic nuclei as well as in the pre-Bötzinger complex, with no data regarding the mRNA expression reported in previous studies [16,17].

Orexin mediates multiple biological functions, such as arousal, emotion, cognition, reward system, metabolism, and autonomic function [10,13,14]. OX2R expression in the abovementioned brain regions could contribute to the functions of orexin: moderate to high OX2R expression in the retrosplenial cortex, prelimbic cortex, cingulate cortex, insular cortex, hippocampus, basolateral amygdala, cortical amygdala, and some thalamic nuclei related to arousal, emotion, and cognition; nucleus accumbens shell and ventral pallidum related to the motivation/reward system; and the pre-Bötzinger complex correlated with autonomic function. In addition, this expression profiling could further clarify OX2R contribution in additional biological functions. For example, increasing evidence suggests the role of the retrosplenial cortex in conjunction with the hippocampus in memory formation during sleep [27-29]. A relatively high expression of OX2R protein in the retrosplenial cortex and hippocampus might indicate the role of OX2R in cognition not only during wakefulness but also during sleep. The suprachiasmatic nucleus of the hypothalamus, responsible for circadian regulation, also unexpectedly exhibited a relatively high OX2R protein expression. Orexin neurons receive indirect and direct projections from the suprachiasmatic nucleus of the hypothalamus [30,31] to produce diurnal fluctuations in orexin production in rats [32,33]. Reciprocally, orexin-A immunoreactive fibers are distributed in the suprachiasmatic nucleus of the hypothalamus, wherein orexin-A suppresses the activity of clock cells [34]. The high expression of OX2R in the suprachiasmatic nucleus of the hypothalamus further suggests the critical role of OX2R in circadian regulation, and OX2R agonists could be effective in treating disorders associated with circadian rhythm disruption, such as shift-work disorder. Detailed functional studies using OX2R-selective agonists are necessary for exploring these hypotheses.

Monoaminergic and cholinergic pathways contribute to multiple orexinergic functions, such as arousal and the motivation/reward processes [10]. Orexin neurons densely innervate the following monoaminergic nuclei: noradrenergic locus coeruleus, histaminergic tuberomammillary nucleus of the hypothalamus, serotonergic raphe nuclei, dopaminergic ventral tegmental area, cholinergic pedunculopontine tegmental, and laterodorsal tegmental nuclei. In this study, a relatively high expression of OX2R was observed in both the ventral tuberomammillary nucleus of the hypothalamus and the raphe nuclei (dorsal and median), suggesting the significant role of OX2R in histaminergic and serotonergic nuclei, which was consistent with previous reports [11,14,35]. In addition, moderate levels of OX2R protein expression were also observed in the locus coeruleus, pedunculopontine tegmental nucleus, and laterodorsal tegmental nucleus. Although OX1R is perceived to play exclusive roles in these regions [11,14,35], OX2R may also contribute to the activation of noradrenergic and cholinergic neurons. A previous study demonstrated the expression of OX2R mRNA in non-monoaminergic neurons in the locus coeruleus and GABAergic neurons in the pedunculopontine tegmental and laterodorsal tegmental nuclei [36]. Therefore, OX2R functions in noradrenergic and cholinergic nuclei should be carefully investigated. The dopaminergic ventral tegmental area showed low levels of OX2R protein expression, suggesting the minor role of OX2R in dopaminergic nuclei.

In rat peripheral tissue sections, OX2R protein expression was mostly negligible, but detected at very low levels in the adrenal cortex, consistent with previously reported mRNA expression [18,37]. Several reports have suggested that orexin stimulates glucocorticoid secretion from adrenocortical cells [38-40]. Glucocorticoid secretion by the adrenal gland is regulated by the hypothalamus-pituitary-adrenal axis, which comprises the paraventricular nucleus of the hypothalamus, the pituitary gland, and the adrenal cortex. As high levels of OX2R protein expression were detected in the paraventricular nucleus of the hypothalamus, OX2R in both the central and peripheral regions may be involved in glucocorticoid secretion. We also observed extremely low OX2R protein expression in the kidney cortex; however, the renal function of OX2R is currently unknown. Detailed functional studies using OX2R-selective agonists, along with an evaluation of the peripheral orexin levels, are needed to further verify OX2R function in these peripheral tissues. The level of blood-brain barrier penetration by orexin is extremely low [41]; thus, the possibility of orexin production in peripheral tissues should also be considered. In fact, low levels of prepro-orexin mRNA were detected in some peripheral tissues, including rat testis [1,18], and there are some reports on the low levels of plasma orexin-A measured using radioimmunoassay (RIA) [42,43]. However, a recent report indicated that conventional RIA for orexin-A largely measures unauthentic orexin-A-related metabolites [44]. Better methods, including recently reported liquid chromatography mass spectrometry assays [45-47], should be used for accurately measuring orexin-A levels.

A limitation of this study is that the location of the small brain regions determined using only stereotaxic coordinates may not be precise. In addition, this study did not identify the OX2R-expressing cell types. Further studies are required to identify precise brain regions and cell types with specific markers.

In conclusion, our data demonstrated the widespread distribution of OX2R protein expression in the rat brain. In contrast, nearly undetectable or very low levels of OX2R protein expression was observed in the peripheral tissues, indicating that orexin performs OX2R-dependent physiological functions primarily via the activation of the central nervous system. Considering the diverse range of biological functions performed by OX2R, our data would be useful for elucidating the physiological functions and underlying mechanisms of action of OX2R agonists. The evaluation of OX2R protein expression in animal models and human postmortem tissues using in vitro autoradiography with [³H]-EMPA could also improve our understanding of the implication of OX2R in various disorders. The clinical development of our OX2R agonists is currently underway (ClinicalTrials.gov Identifier: NCT04091438, NCT04820842, NCT04096560).

Animals

OX2R KO mice and their littermate WT mice were bred in our laboratory. Nineteen-week-old male OX2R KO mice and their littermate WT mice were used to evaluate the selectivity of [³H]-EMPA for OX2R. All mice were housed under ethical laboratory conditions (12 h light/dark cycles: lights on at 7:00) with food (CE-2, CLEA Japan Inc.) and water available ad libitum. Animals were maintained and sacrificed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of Takeda Pharmaceutical Company Limited, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

Male Sprague–Dawley rats (approximately 250 g, Charles River, Italy) were used to evaluate OX2R expression in the brain sections and peripheral tissue sections. All rats were housed under ethical laboratory conditions (12 h light/dark cycles, lights on at 6:00) with food (rat and mouse maintenance diet Altromin R, A. Rieper SpA, Bolzano, Italy) and water available ad libitum.

OX2R expression studies were conducted in Aptuit (Verona) Srl under the approval of the internal Aptuit Committee on Animal Research and Ethics, with authorization issued by the Italian Ministry of Health (Italian Ministry of Health Authorization Project). General procedures for animal care and housing were in accordance with the current AAALAC recommendations.

All animal experiments were performed in accordance with ARRIVE guidelines.

Chemicals and radiolabeled ligand

[³H]-EMPA (specific activity: 79 Ci/mmol) was purchased from Novandi Chemistry AB (Södertälje, Sweden). Additionally, JNJ-10397049 was synthesized by Aptuit (Verona) Srl (Verona, Italy), and 2-methylbutane was purchased from Fujifilm Wako Pure Chemical Co. (Osaka, Japan).

Preparation of mice brain sections

Immediately following euthanasia, the brains of adult OX2R KO mice and their littermate WT mice (n = 4 per group) were rapidly dissected and promptly frozen in pre-cooled (-30 to -20°C) 2-methylbutane in dry ice. Coronal sections (14 µm-thick) were dissected at six brain levels corresponding to the regions of interest with reference to stereotaxic coordinates [48] and were mounted on glass slides. The sections were stored at -80°C until autoradiography was performed. All animals were sacrificed according to the guidelines of the IACUC of Takeda Pharmaceutical Company Limited, and the brains were collected at approximately the same time (13:00–15:00) to avoid any possible diurnal variations.

Preparation of rat brain and peripheral tissue/organ sections

Immediately following euthanasia, the brains and 10 peripheral tissues or organs of adult male Sprague–Dawley rats (n = 4 per group) were rapidly dissected and promptly frozen in pre-cooled (-30°C) 2-methylbutane in dry ice. Brains were dissected into 14 µm-thick coronal sections at different levels corresponding to the regions of interest with reference to stereotaxic coordinates [49]. Subsequently, these sections were mounted on glass slides and stored at -80°C until autoradiography was performed. Furthermore, 10 peripheral tissues or organs were dissected into 14 µm-thick coronal sections and mounted on glass slides. These sections were stored at -80°C until autoradiography was performed. During necropsy, parts of the same tissues or organs from all rats were preserved in 10% neutral buffered formalin. After fixation, the tissues were further processed for paraffin embedding into wax blocks, sectioned at a nominal thickness of 35 µm, and stained with hematoxylin-eosin for microscopic examination. All animals were sacrificed, and all samples were collected at approximately the same time (8:00–9:00) to avoid any possible diurnal variations.

OX2R autoradiography

Tissue sections were pre-incubated for 15 min in an assay buffer (25 mM HEPES, 1 mM CaCl₂, and 5 mM MgCl₂; pH 7.4) and subsequently incubated for 60 min at room temperature in the assay buffer supplemented with 3 nM [³H]-EMPA. Thereafter, the sections were washed twice in the assay buffer at 4°C for 1 min and rapidly rinsed in Milli-Q water. The sections were then air-dried and exposed to BAS-TR2025 Fuji imaging plates (Fuji Film, Tokyo, Japan) for 9 d. Subsequently, NSB was estimated in terms of the extent of binding in the presence of excess JNJ-10397049 (an OX2R-selective antagonist) [24,25] (final concentration of 1 µM for the rat study and 10 µM for the mice study). Autoradiograms were generated using a Phospho-Imager Bio-image Analyzer BAS5000 (Fuji Photo Film Co., Japan). The radioactivity of the region of interest was analyzed as photostimulated luminescence per mm² using computer-assisted microdensitometry (MCID basic, Imaging Research, Canada) and was expressed in terms of ROD values.

Four slides were used for each brain or peripheral tissue: three slides for the determination of total binding and one slide for the evaluation of NSB. For each region of interest, the signal density of total binding was measured in duplicate in each section and averaged from the values for three consecutive sections on different slides.

Specific binding was calculated by subtracting NSB from total binding. Because of the slight differences in the background binding level on the glass slides (outside the sections), the following analysis was performed to calculate the specific binding to correct any differences in experimental conditions among the slides: specific binding = (total binding – background) – (NSB – background). The background binding level on each glass slide was calculated as the average of nine spot areas outside the sections on the glass slide.

Comparison of protein expression with reported mRNA expression

Protein expression observed in this study and previously reported mRNA expression [1,16-18] were compared. Protein expression was defined to be higher than mRNA expression if the former was more than low (+) in regions with previously reported undetectable mRNA expression or if it was clearly higher than previously reported mRNA expression (+ for mRNA vs. +++/++++ for protein or ++ for mRNA vs. ++++ for protein). Conversely, lower protein expression than mRNA expression was determined based on the observation of undetectable protein expression in regions where mRNA expression was observed in previous studies. In addition, previous studies on peripheral OX2R mRNA expression did not exhibit no qualitative assessments. The OX2R protein expression level in the adrenal cortex was very low in our study, whereas the OX2R mRNA expression level in the adrenal cortex was the highest among the expression levels in the whole brain and 14 peripheral tissues in a previous study [18]. Therefore, our study reported a decrease in protein expression compared to mRNA expression in the adrenal cortex.

Acknowledgements

We would like to express our sincere gratitude to Dr. Renzo Carletti of Aptuit (Verona) Srl for supporting the study by contributing to the experiments and conducting thoughtful discussions, and Dr. Mauro Corsi of Aptuit (Verona) Srl for his valuable advice.

Author contributions

K.M. and H.K. conceived the study, wrote the manuscript, and organized the data presentation. K.M. contributed by conducting the experiments and analyzing the data. H.K. was in charge of overall direction and planning of the study.

Additional information

This work was funded by Takeda Pharmaceutical Company Limited.

Competing interests statement

The authors declare no competing interests.

Data Availability

All raw data and materials are available on request.

1 Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585, doi:10.1016/s0092-8674(00)80949-6 (1998).

2 de Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95, 322-327, doi:10.1073/pnas.95.1.322 (1998).

3 Nambu, T. et al. Distribution of orexin neurons in the adult rat brain. Brain Res 827, 243-260, doi:10.1016/s0006-8993(99)01336-0 (1999).

4 Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18, 9996-10015 (1998).

5 Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39-40, doi:10.1016/S0140-6736(99)05582-8 (2000).

6 Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6, 991-997, doi:10.1038/79690 (2000).

7 Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469-474, doi:10.1016/s0896-6273(00)00058-1 (2000).

8 Bassetti, C. L. A. et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol 15, 519-539, doi:10.1038/s41582-019-0226-9 (2019).

9 Thorpy, M. J. & Dauvilliers, Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med 16, 9-18, doi:10.1016/j.sleep.2014.10.002 (2015).

10 Tsujino, N. & Sakurai, T. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci 7, 28, doi:10.3389/fnbeh.2013.00028 (2013).

11 Sakurai, T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8, 171-181, doi:10.1038/nrn2092 (2007).

12 Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376, doi:10.1016/s0092-8674(00)81965-0 (1999).

13 Sakurai, T. The role of orexin in motivated behaviours. Nat Rev Neurosci 15, 719-731, doi:10.1038/nrn3837 (2014).

14 Scammell, T. E. & Winrow, C. J. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51, 243-266, doi:10.1146/annurev-pharmtox-010510-100528 (2011).

15 Yukitake, H. et al. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacol Biochem Behav 187, 172794, doi:10.1016/j.pbb.2019.172794 (2019).

16 Marcus, J. N. et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435, 6-25, doi:10.1002/cne.1190 (2001).

17 Trivedi, P., Yu, H., MacNeil, D. J., Van der Ploeg, L. H. & Guan, X. M. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 438, 71-75, doi:10.1016/s0014-5793(98)01266-6 (1998).

18 Johren, O., Neidert, S. J., Kummer, M., Dendorfer, A. & Dominiak, P. Prepro-orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 142, 3324-3331, doi:10.1210/endo.142.8.8299 (2001).

19 Manuel, I. et al. Neurotransmitter receptor localization: from autoradiography to imaging mass spectrometry. ACS Chem Neurosci 6, 362-373, doi:10.1021/cn500281t (2015).

20 Malherbe, P. et al. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 156, 1326-1341, doi:10.1111/j.1476-5381.2009.00127.x (2009).

21 Salomon, R. M. et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 54, 96-104, doi:10.1016/s0006-3223(02)01740-7 (2003).

22 Yoshida, Y. et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14, 1075-1081, doi:10.1046/j.0953-816x.2001.01725.x (2001).

23 Zeitzer, J. M. et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 23, 3555-3560 (2003).

24 McAtee, L. C. et al. Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett 14, 4225-4229, doi:10.1016/j.bmcl.2004.06.032 (2004).

25 Piccoli, L. et al. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology 37, 1999-2011, doi:10.1038/npp.2012.48 (2012).

26 Hirose, M. et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett 13, 4497-4499, doi:10.1016/j.bmcl.2003.08.038 (2003).

27 de Almeida-Filho, D. G. et al. Hippocampus-retrosplenial cortex interaction is increased during phasic REM and contributes to memory consolidation. Sci Rep 11, 13078, doi:10.1038/s41598-021-91659-5 (2021).

28 Koike, B. D. V. et al. Electrophysiological Evidence That the Retrosplenial Cortex Displays a Strong and Specific Activation Phased with Hippocampal Theta during Paradoxical (REM) Sleep. J Neurosci 37, 8003-8013, doi:10.1523/JNEUROSCI.0026-17.2017 (2017).

29 Opalka, A. N., Huang, W. Q., Liu, J., Liang, H. & Wang, D. V. Hippocampal Ripple Coordinates Retrosplenial Inhibitory Neurons during Slow-Wave Sleep. Cell Rep 30, 432-441 e433, doi:10.1016/j.celrep.2019.12.038 (2020).

30 Scammell, T. E., Arrigoni, E. & Lipton, J. O. Neural Circuitry of Wakefulness and Sleep. Neuron 93, 747-765, doi:10.1016/j.neuron.2017.01.014 (2017).

31 Abrahamson, E. E., Leak, R. K. & Moore, R. Y. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 12, 435-440, doi:10.1097/00001756-200102120-00048 (2001).

32 Deboer, T. et al. Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neuroscience 129, 727-732, doi:10.1016/j.neuroscience.2004.07.049 (2004).

33 Zhang, S. et al. Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Sleep 27, 619-627, doi:10.1093/sleep/27.4.619 (2004).

34 Belle, M. D. et al. Acute suppressive and long-term phase modulation actions of orexin on the mammalian circadian clock. J Neurosci 34, 3607-3621, doi:10.1523/JNEUROSCI.3388-13.2014 (2014).

35 Equihua, A. C., De La Herran-Arita, A. K. & Drucker-Colin, R. Orexin receptor antagonists as therapeutic agents for insomnia. Front Pharmacol 4, 163, doi:10.3389/fphar.2013.00163 (2013).

36 Mieda, M. et al. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 31, 6518-6526, doi:10.1523/JNEUROSCI.6506-10.2011 (2011).

37 Randeva, H. S., Karteris, E., Grammatopoulos, D. & Hillhouse, E. W. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J Clin Endocrinol Metab 86, 4808-4813, doi:10.1210/jcem.86.10.7921 (2001).

38 Mazzocchi, G., Malendowicz, L. K., Gottardo, L., Aragona, F. & Nussdorfer, G. G. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. J Clin Endocrinol Metab 86, 778-782, doi:10.1210/jcem.86.2.7233 (2001).

39 Wenzel, J. et al. Hypocretin/orexin increases the expression of steroidogenic enzymes in human adrenocortical NCI H295R cells. Am J Physiol Regul Integr Comp Physiol 297, R1601-1609, doi:10.1152/ajpregu.91034.2008 (2009).

40 Ziolkowska, A. et al. Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor. J Steroid Biochem Mol Biol 96, 423-429, doi:10.1016/j.jsbmb.2005.05.003 (2005).

41 Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E. & Nishino, S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26, 953-959, doi:10.1093/sleep/26.8.953 (2003).

42 Dalal, M. A. et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 56, 1749-1751, doi:10.1212/wnl.56.12.1749 (2001).

43 Makela, K. A. et al. Plasma Orexin-A Levels Do Not Undergo Circadian Rhythm in Young Healthy Male Subjects. Front Endocrinol (Lausanne) 9, 710, doi:10.3389/fendo.2018.00710 (2018).

44 Sakai, N., Matsumura, M., Lin, L., Mignot, E. & Nishino, S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. Sci Rep 9, 477, doi:10.1038/s41598-018-36942-8 (2019).

45 Bardsen, K. et al. Considerably Lower Levels of Hypocretin-1 in Cerebrospinal Fluid Is Revealed by a Novel Mass Spectrometry Method Compared with Standard Radioimmunoassay. Anal Chem 91, 9323-9329, doi:10.1021/acs.analchem.9b02710 (2019).

46 Hirtz, C. et al. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci Rep 6, 25162, doi:10.1038/srep25162 (2016).

47 Lindstrom, M. et al. Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays. Clin Biochem 90, 34-39, doi:10.1016/j.clinbiochem.2021.01.009 (2021).

48 George Paxinos, K. B. J. F. The Mouse Brain in Stereotaxic Coordinates, Fourth Edition. Academic Press (2012).

49 George Paxinos, C. W. The rat brain atlas in stereotaxic coordinates, Fourth Edition. Academic press (1998).

Table 1. Relative densities of [³H]-EMPA binding for OX2R protein expression in rat brain sections.

Qualitative estimates of OX2R protein expression are presented based on the relative optical density (ROD) values of [³H]-EMPA binding (Supplementary Table S1). The following scale was used: ++++, very high density (ROD ≥ 12); +++, high density (8 ≤ ROD < 12); ++, moderate density (4 ≤ ROD < 8); +, low density (1 ≤ ROD < 4); and -, nearly undetectable density (ROD < 1). Difference from the reported OX2R mRNA levels [16,17] is also depicted. A relatively higher protein expression than the reported mRNA expression is indicated by “↑.” No reported data of mRNA expression in previous comprehensive assessments is represented as “NR.”

Brain Area

OX2R protein level

Difference from reported OX2R mRNA level [16, 17]

Brain Area

OX2R protein level

Difference from reported OX2R mRNA level [16, 17]

Cortex

Piriform cortex

Infralimbic cortex

Retrosplenial cortex

Prelimbic cortex

Cingulate cortex

Motor cortex

Somatosensory cortex

Internal layer of cortex

Insular cortex

Cerebellum

Hippocampus and Septum

CA1

CA3

Lateral septum

Medial septum

Lateral septum dorsal part

Triangular septum

Basal ganglia

Caudate putamen

Nucleus accumbens (core)

Nucleus accumbens (shell)

Globus pallidus

Ventral pallidum

Substantia nigra

Amygdala

Basolateral amygdala

Cortical amygdala

+++

++++

+++

++++

↑

Subfornical organ

Hypothalamus

Dorsomedial nucleus

Ventromedial nucleus

Paraventricular nucleus

Magnocellular preoptic area

Lateral preoptic area

Medial preoptic area

Ventral tuberomammillary nucleus

Suprachiasmatic nucleus

Mammillary nuclei

Thalamus

Medial geniculate nucleus

Dorsolateral geniculate nucleus

Ventromedial thalamic nucleus

Central medial thalamic nucleus

Laterodorsal thalamic nucleus

Midbrain, Pons and Medulla

Superior colliculus

Ventral tegmental area

Periaqueductal gray

Dorsal raphe nucleus

Median raphe nucleus

Pontine nuclei

Locus coeruleus

Pedunculopontine tegmental nucleus

Laterodorsal tegmental nucleus

Barrington’s nucleus

Pre-Bötzinger complex

+++

↑

Table 2. Relative densities of [³H]-EMPA binding for OX2R protein expression in rat peripheral tissue sections.

Qualitative estimates of OX2R protein expression are presented based on the relative optical density (ROD) values for [³H]-EMPA binding (Supplementary Table S2). The following scale was used: +, low density (1 ≤ ROD < 4); -, nearly undetectable density (ROD < 1). Difference from reported OX2R mRNA expression [1,18] is also depicted. A relatively higher or lower protein expression than the reported mRNA expression is indicated by “↑” or “↓,” respectively. No reported data of mRNA expression in comprehensive assessments is represented as “NR.”

Peripheral tissue

OX2R protein level

Difference from reported OX2R mRNA level [1, 18]

Heart

Testis

Adrenal gland

Adrenal Med

Adrenal Cortex

Gut

Gut Mucosa

Gut Muscle

Kidney Cortex

Pituitary

Skeletal muscle

Thyroid

Lung

Bladder muscle

↓

↑

↓

No competing interests reported.

SupplementaryInformationFinal.pdf

Download PDF

Journal Publication

published 18 May, 2022

Read the published version in Scientific Reports →

Editorial decision: Major revision
17 Dec, 2021
Reviews received at journal
16 Dec, 2021
Reviewers agreed at journal
09 Dec, 2021
Reviewers invited by journal
09 Dec, 2021
Editor assigned by journal
09 Dec, 2021
Editor invited by journal
09 Dec, 2021
Submission checks completed at journal
09 Dec, 2021
First submitted to journal
06 Dec, 2021

You are reading this latest preprint version

Orexin 2 Receptor (OX2R) Protein Distribution Measured by Autoradiography Using Radiolabeled OX2R-Selective Antagonist EMPA in Rodent Brain and Peripheral Tissues

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Results

Discussion

Methods

Animals

Chemicals and radiolabeled ligand

Preparation of mice brain sections

Preparation of rat brain and peripheral tissue/organ sections

OX2R autoradiography

Comparison of protein expression with reported mRNA expression

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1